samplerecombinant GH
99%+ · 12mg · Lyophilized
Bulk discount
3+ pcs
€113.05
−5%
5+ pcs
€107.10
−10%
10+ pcs
€101.15
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
HGH 191AA (Somatropin)
Somatropin | Recombinant Human Growth Hormone | Metabolic Regulator
In short
Recombinant 191-amino acid somatropin studied as the gold standard in models of growth and metabolic regulation.
Best sellers
Related resources
Ready-to-use starter kit
HGH 191AA (Somatropin) is a recombinant peptide that contains the exact same sequence of 191 amino acids found in natural human growth hormone. At the molecular level, it binds to specific cell surface receptors, prompting the liver to synthesize insulin-like growth factor 1 (IGF-1) and regulating cellular reproduction and metabolism. Researchers study this molecule in laboratory (in vitro) and animal models to evaluate its mechanisms related to lipolysis and tissue regeneration. While somatropin is the active pharmaceutical ingredient in several approved medications for hormone deficiency, this specific product is research-grade and is strictly not a medicine for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
HGH 191AA is a recombinant human growth hormone containing the exact 191-amino acid sequence found in endogenous pituitary growth hormone. It is produced using recombinant DNA technology in Escherichia coli. The peptide acts as a primary endocrine regulator of growth, cellular reproduction, and metabolic homeostasis. Exogenous administration aims to restore physiological growth hormone levels in cases of deficiency or age-related decline. The lyophilized formulation ensures stability until reconstitution for subcutaneous delivery.
Full-length 191-aa somatropin - identical to native HGH First peptide hormone from recombinant DNA (Genentech 1981) JAK2/STAT5 → IGF-1 expression in hepatocytes Reference for anabolic research applications
Somatropin binds to the growth hormone receptor on the cell surface, inducing receptor dimerization and activating the JAK2/STAT5 signaling cascade. This activation stimulates the liver to synthesize and secrete insulin-like growth factor 1 (IGF-1), which mediates most anabolic and anti-apoptotic effects in peripheral tissues. Independent of IGF-1, the hormone directly stimulates lipolysis in adipocytes via hormone-sensitive lipase and promotes glycogenolysis in the liver.
Somatropin stimulates protein synthesis and amino acid uptake in skeletal muscle. This process is heavily mediated by the upregulation of IGF-1.
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Administer before bed to mimic natural pulsatile release.
Split into two doses if exceeding 3 IU to maintain stable blood levels.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Administer in the evening before bed to align with natural nocturnal growth hormone pulses, or split into morning and evening doses.
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 17
17marks
Standard insulin syringe 1 ml (100 marks)
Concentration
6.00mg/ml
Dose volume
0.167ml
U-100 units
17units
Doses per vial
12doses
Recommended needle
29G / 1 ml insulin
Standard for peptide dosing — widely stocked
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (12 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Administer in the evening before bed to align with natural nocturnal growth hormone pulses, or split into morning and evening doses.
In clinical settings, somatropin dosage is highly individualized based on body weight, IGF-1 levels, and therapeutic response. Doses are titrated slowly to minimize side effects like edema and arthralgia.
Important
In clinical settings, somatropin dosage is highly individualized based on body weight, IGF-1 levels, and therapeutic response. Doses are titrated slowly to minimize side effects like edema and arthralgia.
Remove the HGH vial and bacteriostatic water from the refrigerator and allow them to reach room temperature.
Wipe the rubber stoppers of both vials with an alcohol swab.
Draw the appropriate volume of bacteriostatic water into a sterile syringe.
Inject the water slowly into the HGH vial, aiming the stream at the glass wall to avoid damaging the peptide.
Swirl the vial gently in a circular motion until the powder is completely dissolved. Do not shake.
Store the reconstituted solution in the refrigerator immediately.
May cause transient fluid retention and peripheral edema during initial weeks of therapy.
Can induce insulin resistance and elevate fasting blood glucose levels.
Carpal tunnel syndrome or joint pain may occur at higher dosages.
Contraindicated in individuals with active malignancies or acute critical illness.
Requires regular monitoring of , fasting glucose, and thyroid function.
Long-term supraphysiological dosing increases the risk of acromegaly-like symptoms.
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Effects of human growth hormone in men over 60 years old
Human | 21 subjects | 6 months | Lean body mass and adipose tissue
Administration of human growth hormone for six months in healthy older men increased lean body mass by 8.8 percent. The treatment simultaneously decreased adipose-tissue mass by 14.4 percent and increased skin thickness.
View the studyEfficacy and tolerability of growth hormone treatment in adults with growth hormone deficiency
Human | Meta-analysis | Long-term | Body composition and bone density
Long-term somatropin replacement therapy in adults with growth hormone deficiency normalizes body composition and improves bone mineral density. The therapy also demonstrates positive effects on cardiovascular risk factors.
Growth hormone treatment of abdominally obese men reduces abdominal fat mass
Human | 30 subjects | 9 months | Visceral fat and insulin sensitivity
Nine months of growth hormone treatment in abdominally obese men significantly reduced visceral adipose tissue. The intervention improved the overall lipoprotein profile and reduced diastolic blood pressure.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
